AR093505A1 - Derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina que contienen un grupo sulfoximina - Google Patents
Derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina que contienen un grupo sulfoximinaInfo
- Publication number
- AR093505A1 AR093505A1 ARP130104211A ARP130104211A AR093505A1 AR 093505 A1 AR093505 A1 AR 093505A1 AR P130104211 A ARP130104211 A AR P130104211A AR P130104211 A ARP130104211 A AR P130104211A AR 093505 A1 AR093505 A1 AR 093505A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- alkoxy
- acetylamino
- halo
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Derivados de 5-fluoro-N-(piridin-2-il)-piridin-2-amina que contienen un grupo sulfoximina y que presentan la fórmula general (1), como se describen y definen en la presente. Métodos para prepararlas. Su uso en el tratamiento y/o la profilaxis de diversos trastornos, particularmente de los trastornos hiperproliferativos, de las enfermedades infecciosas inducidas por virus y/o de las enfermedades cardiovasculares. Compuestos intermediarios útiles para preparar los compuestos de fórmula general (1). Reivindicación 1: Un compuesto de fórmula general (1) donde R¹ representa un grupo seleccionado entre alquilo C₁₋₆, cicloalquilo C₃₋₇, heterociclilo, fenilo, heteroarilo, fenil-alquilo C₁₋₃ o heteroaril-alquilo C₁₋₃, donde dicho grupo está opcionalmente sustituido con uno o dos o tres sustituyentes, de manera idéntica o diferente, seleccionados entre el grupo que consiste en hidroxi, ciano, halógeno, halo-alquilo C₁₋₃, alcoxi C₁₋₆, fluoro-alcoxi C₁₋₃, -NH₂, alquilamino, dialquilamino, acetilamino, N-metil-N-acetilamino, aminas cíclicas, -OP(O)(OH)₂, -C(O)OH, -C(O)NH₂; R² representa un grupo seleccionado entre el grupo de fórmulas (2); R³, R⁴ representan, en forma independiente entre sí, un grupo seleccionado entre un átomo de hidrógeno, átomo de flúor, átomo de cloro, átomo de bromo, ciano, alquilo C₁₋₃, alcoxi C₁₋₃, halo-alquilo C₁₋₃, fluoro-alcoxi C₁₋₃; R⁵ representa un grupo seleccionado entre un átomo de hidrógeno, ciano, -C(O)R⁹, -C(O)OR⁹, -S(O)₂R⁹, -C(O)NR¹⁰R¹¹, -P(O)(OR¹²)₂, -CH₂OP(OR¹²)₂, alquilo C₁₋₆, cicloalquilo C₃₋₇, heterociclilo, fenilo, heteroarilo, donde dicho grupo alquilo C₁₋₆, cicloalquilo C₃₋₇, heterociclilo, fenilo o heteroarilo está opcionalmente sustituido con uno, dos o tres sustituyentes, de manera idéntica o diferente, seleccionados entre halógeno, hidroxi, ciano, alquilo C₁₋₃, alcoxi C₁₋₃, -NH₂, alquilamino, dialquilamino, acetilamino, N-metil-N-acetilamino, aminas cíclicas, halo-alquilo C₁₋₃, fluoro-alcoxi C₁₋₃; R⁶, R⁷ representan, en forma independiente entre sí, un grupo seleccionado entre un átomo de hidrógeno, átomo de flúor, átomo de cloro, alquilo C₁₋₃, alcoxi C₁₋₃, halo-alquilo C₁₋₃, fluoro-alcoxi C₁₋₃; R⁸ representa un grupo seleccionado entre a) un grupo alquilo C₁₋₆, que está opcionalmente sustituido con uno o dos o tres sustituyentes, de manera idéntica o diferente, seleccionados entre halógeno, hidroxi, -NH₂, alquilamino, dialquilamino, acetilamino, N-metil-N-acetilamino, aminas cíclicas, ciano, alquilo C₁₋₃, halo-alquilo C₁₋₃, fluoro-alcoxi C₁₋₃, alcoxi C₁₋₃, alquenilo C₂₋₃, alquinilo C₂₋₃, cicloalquilo C₃₋₇, heterociclilo, fenilo, heteroarilo, donde dicho grupo cicloalquilo C₃₋₇, heterociclilo, fenilo o heteroarilo está opcionalmente sustituido con uno, dos o tres sustituyentes, de manera idéntica o diferente, seleccionados entre halógeno, hidroxi, alquilo C₁₋₃, alcoxi C₁₋₃, -NH₂, alquilamino, dialquilamino, acetilamino, N-metil-N-acetilamino aminas cíclicas, halo-alquilo C₁₋₃, fluoro-alcoxi C₁₋₃; b) un grupo cicloalquilo C₃₋₇, que está opcionalmente sustituido con uno o dos o tres sustituyentes, de manera idéntica o diferente, seleccionados entre el grupo que consiste en halógeno, hidroxi, -NH₂, alquilamino, dialquilamino, acetilamino, N-metil-N-acetilamino, aminas cíclicas, ciano, alquilo C₁₋₃, halo-alquilo C₁₋₃, fluoro-alcoxi C₁₋₃, alcoxi C₁₋₃, alquenilo C₂₋₃, alquinilo C₂₋₃; c) un grupo heterociclilo, que está opcionalmente sustituido con uno o dos o tres sustituyentes, de manera idéntica o diferente, seleccionados entre el grupo que consiste en halógeno, hidroxi, -NH₂, alquilamino, dialquilamino, acetilamino, N-metil -N-acetilamino, aminas cíclicas, ciano, alquilo C₁₋₃, halo-alquilo C₁₋₃, fluoro-alcoxi C₁₋₃, alcoxi C₁₋₃, alquenilo C₂₋₃, alquinilo C₂₋₃; d) un grupo fenilo, que está opcionalmente sustituido con uno o dos o tres sustituyentes, de manera idéntica o diferente, seleccionados entre el grupo que consiste en halógeno, hidroxi, -NH₂, alquilamino, dialquilamino, acetilamino, N-metil-N-acetilamino, aminas cíclicas, ciano, alquilo C₁₋₃, halo-alquilo C₁₋₃, fluoro-alcoxi C₁₋₃, alcoxi C₁₋₃; e) un grupo heteroarilo, que está opcionalmente sustituido con uno o dos o tres sustituyentes, de manera idéntica o diferente, seleccionados entre el grupo que consiste en halógeno, hidroxi, -NH₂, alquilamino, dialquilamino, acetilamino, N-metil-N-acetilamino, aminas cíclicas, ciano, alquilo C₁₋₃, halo-alquilo C₁₋₃, fluoro-alcoxi C₁₋₃, alcoxi C₁₋₃; f) un grupo fenil-alquilo C₁₋₃, donde el grupo fenilo del mismo está opcionalmente sustituido con uno o dos o tres sustituyentes, de manera idéntica o diferente, seleccionados entre el grupo que consiste en halógeno, hidroxi, -NH₂, alquilamino, dialquilamino, acetilamino, N-metil-N acetilamino, aminas cíclicas, ciano, alquilo C₁₋₃, halo-alquilo C₁₋₃, fluoro-alcoxi C₁₋₃, alcoxi C₁₋₃; g) un grupo heteroaril-cic3alquilo donde el grupo heteroarilo del mismo está opcionalmente sustituido con uno o dos o tres sustituyentes, de manera idéntica o diferente, seleccionados entre el grupo que consiste en halógeno, hidroxi, -NH₂, alquilamino, dialquilamino, acetilamino, N-metil-N-acetilamino aminas cíclicas, ciano, alquilo C₁₋₃, halo-alquilo C₁₋₃, fluoro-alcoxi C₁₋₃, alcoxi C₁₋₃; h) un grupo cicloalquil C₃₋₆-alquilo C₁₋₃ donde el grupo cicloalquilo C₃₋₆ del mismo está opcionalmente sustituido con uno o dos o tres Sustituyentes de manera idéntica o diferente, seleccionados entre halógeno, alquilo C₁₋₃, alcoxi C₁₋₃, halo-alquilo C₁₋₃ fluoro-alcoxi C₁₋₃; i) un grupo heterociclil-alquilo C₁₋₃, donde el grupo heterociclilo del mismo está opcionalmente sustituido con uno o dos o tres sustituyentes, de manera idéntica o diferente, seleccionados entre halógeno, alquilo C₁₋₃, alcoxi C₁₋₃, halo-alquilo C₁₋₃, fluoro-alcoxi C₁₋₃; R⁹ representa un grupo seleccionado entre alquilo C₁₋₆, halo-alquilo C₁₋₃ cicloalquilo C₃₋₇, heterociclilo, fenilo, bencilo o heteroarilo, donde dicho grupo está opcionalmente sustituido con uno, dos o tres sustituyentes, de manera idéntica o diferente, seleccionados entre halógeno, hidroxi, alquilo C₁₋₃, alcoxi C₁₋₃, -NH₂, alquilamino, dialquilamino, acetilamino, N-metil-N-acetilamino, aminas cíclicas, halo alquilo C₁₋₃, fluoro-alcoxi C₁₋₃; R¹⁰, R¹¹ representan, en forma independiente entre sí, un grupo seleccionado entre hidrógeno, alquilo C₁₋₆, cicloalquilo C₃₋₇, heterociclilo, fenilo, bencilo o heteroarilo, donde dicho grupo alquilo C₁₋₆, cicloalquilo C₃₋₇, heterociclilo, fenilo, bencilo o heteroarilo está opcionalmente sustituido con uno, dos o tres sustituyentes, de manera idéntica o diferente, seleccionados entre halógeno, hidroxi, alquilo C₁₋₃, alcoxi C₁₋₃, -NH₂, alquilamino, dialquilamino, acetilamino, N-metil -N-acetilamino, aminas cíclicas, halo-alquilo C₁₋₃, fluoro-alcoxi C₁₋₃, o R¹⁰ y R¹¹, junto con el átomo de nitrógeno al que están unidos, forman una amina cíclica; R¹² representa un grupo seleccionado entre hidrógeno, alquilo C₁₋₄ o bencilo; y los enantiómeros, diasterómeros, sales, solvatos o sales de solvatos del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12192852 | 2012-11-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR093505A1 true AR093505A1 (es) | 2015-06-10 |
Family
ID=47148672
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130104211A AR093505A1 (es) | 2012-11-15 | 2013-11-15 | Derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina que contienen un grupo sulfoximina |
Country Status (43)
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6858615B2 (en) | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenyl guanidine sodium channel blockers |
TWI555737B (zh) | 2011-05-24 | 2016-11-01 | 拜耳知識產權公司 | 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺 |
AR086745A1 (es) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida |
US9670161B2 (en) | 2012-10-18 | 2017-06-06 | Bayer Pharma Aktiengesellschaft | 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group |
EP2909200B1 (en) | 2012-10-18 | 2016-11-23 | Bayer Pharma Aktiengesellschaft | N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group |
CA2891358C (en) | 2012-11-15 | 2021-05-18 | Bayer Pharma Aktiengesellschaft | 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group |
TW201418243A (zh) | 2012-11-15 | 2014-05-16 | Bayer Pharma AG | 含有磺醯亞胺基團之n-(吡啶-2-基)嘧啶-4-胺衍生物 |
CN104995178B (zh) | 2012-12-17 | 2018-06-26 | 帕里昂科学公司 | 3,5-二氨基-6-氯-n-(n-(4-苯基丁基)甲脒基)吡嗪-2-甲酰胺化合物 |
GEP20186903B (en) | 2012-12-17 | 2018-10-25 | Saiensis Ink Perion | Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration |
WO2015001021A1 (en) * | 2013-07-04 | 2015-01-08 | Bayer Pharma Aktiengesellschaft | Sulfoximine substituted 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives and their use as cdk9 kinase inhibitors |
US9102633B2 (en) | 2013-12-13 | 2015-08-11 | Parion Sciences, Inc. | Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds |
JP2017508757A (ja) | 2014-03-13 | 2017-03-30 | バイエル ファーマ アクチエンゲゼルシャフト | スルホン基を含有する5−フルオロ−n−(ピリジン−2−イル)ピリジン−2−アミン誘導体 |
JP6503372B2 (ja) | 2014-04-01 | 2019-04-17 | バイエル ファーマ アクチエンゲゼルシャフト | スルホンジイミン基を含むジ置換5−フルオロピリミジン誘導体 |
JP6605493B2 (ja) | 2014-04-11 | 2019-11-13 | バイエル ファーマ アクチエンゲゼルシャフト | 新規大環状化合物 |
EP3207037B1 (en) | 2014-10-16 | 2019-01-23 | Bayer Pharma Aktiengesellschaft | Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfone group |
CA2964696C (en) | 2014-10-16 | 2022-09-06 | Bayer Pharma Aktiengesellschaft | Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group |
WO2017055196A1 (en) | 2015-09-29 | 2017-04-06 | Bayer Pharma Aktiengesellschaft | Novel macrocyclic sulfondiimine compounds |
ES2819869T3 (es) | 2015-10-08 | 2021-04-19 | Bayer Pharma AG | Nuevos compuestos macrocíclicos modificados |
WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
WO2018177899A1 (en) | 2017-03-28 | 2018-10-04 | Bayer Aktiengesellschaft | Novel ptefb inhibiting macrocyclic compounds |
WO2018177889A1 (en) | 2017-03-28 | 2018-10-04 | Bayer Aktiengesellschaft | Novel ptefb inhibiting macrocyclic compounds |
WO2019158517A1 (en) * | 2018-02-13 | 2019-08-22 | Bayer Aktiengesellschaft | Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-n-{4-[(s-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large b-cell lymphoma |
WO2021115335A1 (zh) | 2019-12-09 | 2021-06-17 | 石药集团中奇制药技术(石家庄)有限公司 | 作为周期蛋白依赖性激酶9抑制剂的化合物及其应用 |
US20230106032A1 (en) * | 2020-03-06 | 2023-04-06 | Bayer Aktiengesellschaft | Imidazotriazines acting on cancer via inhibition of cdk12 |
CN116249701A (zh) * | 2020-10-12 | 2023-06-09 | 上海海雁医药科技有限公司 | 取代的二(吡啶-2-基)胺衍生物、其组合物及医药上的用途 |
CN117015539A (zh) * | 2022-03-25 | 2023-11-07 | 成都苑东生物制药股份有限公司 | 一种氨基吡啶类衍生物、其制备方法及用途 |
WO2024044757A1 (en) * | 2022-08-26 | 2024-02-29 | Sanford Burnham Prebys Medical Discovery Institute | Aminopyrimidine and aminotriazine derivatives as myc protein modulators |
WO2024097179A1 (en) * | 2022-11-02 | 2024-05-10 | Vincerx Pharma, Inc. | Combination therapies comprising a cdk9 inhibitor for cancer |
WO2024112656A1 (en) * | 2022-11-21 | 2024-05-30 | The Board Of Trustees Of The Leland Stanford Junior University | Use of a tyrosine kinase inhibitor for the treatment of hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE430742T1 (de) | 2000-12-21 | 2009-05-15 | Smithkline Beecham Corp | Pyrimidinamine als angiogenesemodulatoren |
DE10239042A1 (de) | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
DE10349423A1 (de) | 2003-10-16 | 2005-06-16 | Schering Ag | Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
WO2006064251A1 (en) | 2004-12-17 | 2006-06-22 | Astrazeneca Ab | 4- (4- (imidazol-4-yl) pyrimidin-2-ylamino) benzamides as cdk inhibitors |
DE102006041382A1 (de) * | 2006-08-29 | 2008-03-20 | Bayer Schering Pharma Ag | Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren |
DE102006042143A1 (de) | 2006-09-08 | 2008-03-27 | Bayer Healthcare Aktiengesellschaft | Neue substituierte Bipyridin-Derivate und ihre Verwendung |
WO2008060248A1 (en) | 2006-11-15 | 2008-05-22 | S*Bio Pte Ltd. | Indole sustituted pyrimidines and use thereof in the treatment of cancer |
US20100093776A1 (en) | 2006-12-22 | 2010-04-15 | Novartis Ag | Organic Compounds and Their Uses |
EP2094682A2 (en) | 2006-12-22 | 2009-09-02 | Novartis AG | Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections |
WO2008129080A1 (en) | 2007-04-24 | 2008-10-30 | Ingenium Pharmaceuticals Gmbh | 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases |
JP5379787B2 (ja) | 2007-04-24 | 2013-12-25 | インゲニウム ファーマシューティカルズ ジーエムビーエイチ | プロテインキナーゼの阻害剤 |
WO2008129070A1 (en) | 2007-04-24 | 2008-10-30 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
WO2008132138A1 (en) | 2007-04-25 | 2008-11-06 | Ingenium Pharmaceuticals Gmbh | Derivatives of 4,6-disubstituted aminopyrimidines |
WO2009029998A1 (en) | 2007-09-06 | 2009-03-12 | Cytopia Research Pty Ltd | Retrometabolic compounds |
GB0805477D0 (en) | 2008-03-26 | 2008-04-30 | Univ Nottingham | Pyrimidines triazines and their use as pharmaceutical agents |
US8415381B2 (en) | 2009-07-30 | 2013-04-09 | Novartis Ag | Heteroaryl compounds and their uses |
WO2011116951A1 (en) | 2010-03-22 | 2011-09-29 | Lead Discovery Center Gmbh | Pharmaceutically active disubstituted triazine derivatives |
WO2012101063A1 (en) * | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyridine biaryl compounds and their uses |
EP2681193B1 (en) * | 2011-03-02 | 2016-01-06 | Lead Discovery Center GmbH | Pharmaceutically active disubstituted pyridine derivatives |
EP2527332A1 (en) | 2011-05-24 | 2012-11-28 | Bayer Intellectual Property GmbH | 4-Aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group as CDK9 inhibitors |
EP2755956B1 (en) | 2011-09-16 | 2016-05-18 | Bayer Intellectual Property GmbH | 2,4-disubstituted 5-fluoro-pyrimidines as selective cdk9 inhibtors |
CN103930399B (zh) | 2011-09-16 | 2016-03-16 | 拜耳知识产权有限责任公司 | 包含亚氨基亚磺酰基的二取代的5-氟嘧啶衍生物 |
WO2014060376A1 (en) | 2012-10-18 | 2014-04-24 | Bayer Pharma Aktiengesellschaft | 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfone group |
US9670161B2 (en) * | 2012-10-18 | 2017-06-06 | Bayer Pharma Aktiengesellschaft | 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group |
US9499492B2 (en) | 2012-11-15 | 2016-11-22 | Bayer Pharma Aktiengesellschaft | 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfoximine group |
CA2891358C (en) | 2012-11-15 | 2021-05-18 | Bayer Pharma Aktiengesellschaft | 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group |
WO2015001021A1 (en) | 2013-07-04 | 2015-01-08 | Bayer Pharma Aktiengesellschaft | Sulfoximine substituted 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives and their use as cdk9 kinase inhibitors |
JP2017508757A (ja) | 2014-03-13 | 2017-03-30 | バイエル ファーマ アクチエンゲゼルシャフト | スルホン基を含有する5−フルオロ−n−(ピリジン−2−イル)ピリジン−2−アミン誘導体 |
-
2013
- 2013-11-12 CA CA2891358A patent/CA2891358C/en active Active
- 2013-11-12 EP EP13792885.9A patent/EP2928878B1/en active Active
- 2013-11-12 NZ NZ70708413A patent/NZ707084A/en unknown
- 2013-11-12 BR BR112015010707-9A patent/BR112015010707B1/pt active IP Right Grant
- 2013-11-12 SG SG11201503079PA patent/SG11201503079PA/en unknown
- 2013-11-12 LT LTEP13792885.9T patent/LT2928878T/lt unknown
- 2013-11-12 PE PE2015000630A patent/PE20151071A1/es active IP Right Grant
- 2013-11-12 HU HUE13792885A patent/HUE032868T2/en unknown
- 2013-11-12 AU AU2013346939A patent/AU2013346939B2/en active Active
- 2013-11-12 MX MX2015006169A patent/MX2015006169A/es active IP Right Grant
- 2013-11-12 WO PCT/EP2013/073637 patent/WO2014076091A1/en active Application Filing
- 2013-11-12 ES ES13792885.9T patent/ES2612978T3/es active Active
- 2013-11-12 ME MEP-2017-16A patent/ME02880B/me unknown
- 2013-11-12 US US14/443,279 patent/US9650340B2/en active Active
- 2013-11-12 SI SI201330389A patent/SI2928878T1/sl unknown
- 2013-11-12 MA MA38090A patent/MA38090B1/fr unknown
- 2013-11-12 DK DK13792885.9T patent/DK2928878T3/en active
- 2013-11-12 PT PT137928859T patent/PT2928878T/pt unknown
- 2013-11-12 JP JP2015542247A patent/JP6263193B2/ja active Active
- 2013-11-12 MY MYPI2015701520A patent/MY170609A/en unknown
- 2013-11-12 AP AP2015008432A patent/AP3872A/en active
- 2013-11-12 UA UAA201505911A patent/UA115254C2/uk unknown
- 2013-11-12 CN CN201380070440.8A patent/CN105102444B/zh active Active
- 2013-11-12 EA EA201590890A patent/EA027226B1/ru not_active IP Right Cessation
- 2013-11-12 KR KR1020157015423A patent/KR102242871B1/ko active IP Right Grant
- 2013-11-12 PL PL13792885T patent/PL2928878T3/pl unknown
- 2013-11-12 RS RS20170009A patent/RS55580B1/sr unknown
- 2013-11-13 JO JOP/2013/0330A patent/JO3332B1/ar active
- 2013-11-15 TW TW102141761A patent/TWI613193B/zh active
- 2013-11-15 UY UY0001035141A patent/UY35141A/es not_active Application Discontinuation
- 2013-11-15 AR ARP130104211A patent/AR093505A1/es active IP Right Grant
-
2015
- 2015-04-16 IL IL238322A patent/IL238322A/en active IP Right Grant
- 2015-05-05 PH PH12015501003A patent/PH12015501003B1/en unknown
- 2015-05-14 CL CL2015001304A patent/CL2015001304A1/es unknown
- 2015-05-14 TN TNP2015000185A patent/TN2015000185A1/fr unknown
- 2015-05-15 DO DO2015000118A patent/DOP2015000118A/es unknown
- 2015-05-15 EC ECIEPI201519323A patent/ECSP15019323A/es unknown
- 2015-05-15 CU CU2015000052A patent/CU20150052A7/es unknown
- 2015-05-15 CR CR20150256A patent/CR20150256A/es unknown
- 2015-05-15 SV SV2015004979A patent/SV2015004979A/es unknown
-
2016
- 2016-02-02 HK HK16101158.8A patent/HK1213255A1/zh unknown
- 2016-11-22 HR HRP20161547TT patent/HRP20161547T1/hr unknown
-
2017
- 2017-01-17 CY CY20171100053T patent/CY1118441T1/el unknown
- 2017-04-03 US US15/477,974 patent/US9877954B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR093505A1 (es) | Derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina que contienen un grupo sulfoximina | |
AR093504A1 (es) | 4-(orto)-fluorofenil-5-fluoropirimidin-2-ilaminas que contienen un grupo sulfoximina como inhibidores de cdk9, un intermediario para su sintesis y metodos de obtencion de ambos compuestos | |
AR123048A2 (es) | Moduladores de p2x7 | |
AR093503A1 (es) | Derivados de n-(piridin-2-il)pirimidin-4-amina que contienen un grupo sulfoximina | |
AR098136A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
AR087870A1 (es) | Derivados 5-fluoro pirimidina disustituidos que contienen un grupo sulfoximina | |
AR097008A1 (es) | Derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
AR086552A1 (es) | 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina y composicion farmaceutica | |
AR106798A1 (es) | Inhibidores pirazol de acc y usos de los mismos | |
AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
AR102492A1 (es) | Cromanos sustituidos y métodos para su uso | |
AR103222A1 (es) | Procedimiento para la preparación de análogos de 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidina | |
AR089774A1 (es) | Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
AR106297A1 (es) | Compuestos macrocíclicos modificados como inhibidores selectivos de la quinasa cdk9 | |
AR103561A1 (es) | Fenilpiridinas herbicidas | |
AR091498A1 (es) | DERIVADOS DE 2,3-DIHIDRO-1H-IMIDAZO{1,2-a}PIRIMIDIN-5-ONA Y 1,2,3,4-TETRAHIDRO-PIRIMIDO{1,2-a}PIRIMIDIN-6-ONA QUE CONTIENEN UNA MORFOLINA SUSTITUIDA, SU PREPARACION Y SU UTILIZACION FARMACEUTICA | |
AR106604A1 (es) | Compuestos de criptoficina y productos conjugados, su preparación y su uso terapéutico | |
AR088781A1 (es) | Compuestos antimicrobianos y metodos para prepararlos y utilizarlos | |
AR099913A1 (es) | Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
AR091519A1 (es) | Inhibidores pirrolopirazona de tanquirasa | |
AR098492A1 (es) | Derivados de purina | |
AR099914A1 (es) | Derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
AR089776A1 (es) | 5,8-dihidro-6h-pirazolo[3,4-h]quinazolinas como inhibidores de igf-1r/ir | |
AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
AR101359A1 (es) | Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |